Aktienanalyse zu Retension Pharmaceuticals, Inc. Common Stock (RTSN)RTSNRetension Pharmaceuticals, Inc. Common Stock

Retension Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. The Company’s product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (PDE-5) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. RTN-001 is designed to lower blood pressure by potentiating endogenous nitric oxide levels and signaling, thus favoring the restoration of vascular homeostasis. RTN-001 has been evaluated in two randomized, placebo-controlled Phase II pilot trials (Trial 07-05 and Trial 07-08) in adults with hypertension receiving up to four concomitant antihypertensive medications.

Retension Pharmaceuticals may not be a good buy right now due to its current price of $11.44, which is significantly below the analyst's target of $55, but the recent 5-day decline of 19.66% raises concerns about short-term performance. The company has reported negative net income in the last four quarters, with a loss of $4,170,589 in Q2 2026, indicating ongoing financial struggles.